ARDIZZONE, SANDRO
ARDIZZONE, SANDRO
Dipartimento di Scienze Biomediche e Cliniche
Comment on “Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry”
2023 S. Ridolfo, A. Toppeta, A. Dell'Era, S. Ardizzone
Severe chronic diarrhoea caused by hereditary transthyretin amyloidosis
2023 A. Toppeta, A. Dell'Era, P. Molteni, S. Ardizzone
Relevance of sonographic parameters for inflammatory bowel disease in children
2023 A. Dell'Era, R. Cannatelli, F. Ferretti, C. Manzotti, D. Dilillo, G. Zuccotti, F. Meneghin, S. Ardizzone, G. Maconi
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease
2023 M.V. Lenti, M.L. Scribano, L. Biancone, R. Ciccocioppo, D. Pugliese, L. Pastorelli, G. Fiorino, E. Savarino, F.A. Caprioli, S. Ardizzone, M.C. Fantini, G.E. Tontini, A. Orlando, G.M. Sampietro, G.C. Sturniolo, G. Monteleone, M. Vecchi, A. Kohn, M. Daperno, R. D'Incà, G.R. Corazza, A. Di Sabatino
Ultrasonographic and Functional Features of Symptomatic Uncomplicated Diverticular Disease
2023 G. Maconi, A. Dell'Era, N. Flor, A. De Silvestri, A. Lavazza, S. Ardizzone, G. Bassotti
Echo-Endoscopy Combined with Virtual Reality: A Whole Perspective of Laparoscopic Common Bile Duct Exploration in Children
2023 F. Destro, R. Salerno, V. Calcaterra, S. Ardizzone, M. Meroni, M. Roveri, U.M. Pierucci, A. Zaja, F. Rizzetto, A. Campari, M. Vertemati, P. Milani, G. Pelizzo
Gastrointestinal tuberculosis presenting as acute abdomen: a case report
2022 S. Ridolfo, F. Cammarata, A.M. Bonomi, A. Troci, M. Crespi, P. Molteni, A. Pellegrinelli, S. Ardizzone, P. Danelli
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
2022 F.S. Macaluso, A. Orlando, C. Papi, S. Festa, D. Pugliese, S. Bonovas, C. Pansieri, D. Piovani, G. Fiorino, M.C. Fantini, F. Caprioli, M. Daperno, A. Armuzzi, L. Bertani, C. Bezzio, G. Bodini, F. Bossa, A. Buda, E. Calabrese, F. Furfaro, S. Leone, F. Mocciaro, S. Onali, L. Pastorelli, E. Previtali, M. Principi, S. Renna, D.G. Ribaldone, A. Rispo, F. Rizzello, S. Saibeni, G.M. Sampietro, E. Savarino, A. Testa, A. Variola, A. Viscido, S. Ardizzone, L. Biancone, M. Cappello, F. Castiglione, R. Ciccocioppo, M. Comberlato, F. Costa, R. D'Inca, S. Danese, A. Di Sabatino, W. Fries, P. Gionchetti, G. Latella, F. Manguso, M. Mastronardi, G. Meucci, M. Milla, M.L. Scribano, M. Vecchi
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
2022 S. Danese, S. Vermeire, G. D'Haens, J. Panes, A. Dignass, F. Magro, M. Nazar, M. Le Bars, M. Lahaye, L. Ni, I. Bravata, F. Lavie, M. Daperno, M. Lukas, A. Armuzzi, M. Lowenberg, D.R. Gaya, L. Peyrin-Biroulet, R. Rocca, S. Lopes, F. Caprioli, S. Ardizzone, A. Echarri Piudo, P. Gionchetti, X. Roblin, U. Seidler, D. Andersson, K. Patel, P. Desreumaux, S. Saibeni, G. From, M. Fedurco, M. Gregus, Y. Bouhnik, A. Luegering, R. Cosintino, I. Bunganic, J. Ramos, M. Aguas Peris, O. Dewit, M. Principi, E. Wesley, P. Lago, S. Nancey, M.D. Martin Arranz, P. Hindryckx, A. Orlando, A. Geccherle, M.L. Annunziata, B. Hayee, J. Balaz, F. Portela, C. Gilletta, T. Kucharzik, M. Minguez, J.P. Gisbert, A.G. Casbas, E. Louis, M. Marino, G. Parkes, F. Cummings, B. Jharap, J. Kjeldsen, L. Correia, P. Ministro, M. Ebert, E. Hertervig, D. Staessen, J. Dutre, A. Colard, G. Morrison, H. Glerup, J.F. Dahlerup, F. Wolfhagen, M. Batovsky, M. Molnar, B. Kadleckova, P. Caldeira, D. Laharie, X. Hebuterne, B. Bonaz, M. Allez, A. Fischer, J.E. Hinojosa Del Val, M.M. Ciria, J.M. Herrera Justiniano, C. Soderman, R. Chandy, C. Mowat, P. Irving, J. Fallingborg, J. Matous, T. Douda, R. Altwegg, J.M. Benitez, M.T. Arroyo Villarino, J.G. Capon, D.G. Vicenc, P. Dewint, S. Almer, S. Kindt
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
2022 F. Ferretti, R. Cannatelli, M.C. Monico, G. Maconi, S. Ardizzone
Repeated surgery for recurrent Crohn's disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures
2022 F. Colombo, A. Frontali, C. Baldi, M. Cigognini, G. Lamperti, C.A. Manzo, G. Maconi, S. Ardizzone, D. Foschi, G.M. Sampietro
Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study
2022 A. Cassinotti, N. Mezzina, A. De Silvestri, D. Di Paolo, M.V. Lenti, C. Bezzio, D. Stradella, M. Mauri, V. Zadro, C. Ricci, V. Casini, E. Radice, A. Massari, G. Maconi, S. Saibeni, F. Caprioli, R. Tari, M. Fichera, C.C. Cortelezzi, M. Parravicini, C. Tinelli, P.A. Testoni, F. Pace, S. Segato, P. Invernizzi, P. Occhipinti, G. Manes, A. Di Sabatino, L. Pastorelli, M. Vecchi, S. Ardizzone
The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study
2022 F. Ferretti, M.C. Monico, R. Cannatelli, S. Carmagnola, M.V. Lenti, A. Di Sabatino, F. Conforti, L. Pastorelli, F. Caprioli, C. Bezzio, S. Saibeni, S. Mazza, M. Vecchi, G. Maconi, S. Ardizzone
Stem Cell Injection for Complex Refractory Perianal Fistulas in Crohn's Disease: A Single Center Initial Experience
2022 F. Colombo, F. Cammarata, C. Baldi, F. Rizzetto, A. Bondurri, S. Carmagnola, D. Gridavilla, G. Maconi, S. Ardizzone, P. Danelli
Has the Removing of the Mesentery during Ileo-Colic Resection an Impact on Post-Operative Complications and Recurrence in Crohn's Disease? Results from the Resection of the Mesentery Study (Remedy)
2022 M. Mineccia, G. Maconi, M. Daperno, M. Cigognini, V. Cherubini, F. Colombo, S. Perotti, C. Baldi, P. Massucco, S. Ardizzone, A. Ferrero, G.M. Sampietro
Endoscopic management of recurrent cholangitis following EUS-guided choledochoduodenostomy
2022 R. Salerno, N. Mezzina, S. Carmagnola, S. Ardizzone
Anti-tumour necrosis factor α antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease
2021 C. Defendenti, M.S. Tarkowski, S. Borille, A. Cassinotti, A. Massari, S. Birindelli, A. Riva, S. Ardizzone, M. Panteghini
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study
2021 C. Bezzio, A. Armuzzi, F. Furfaro, S. Ardizzone, M. Milla, S. Carparelli, A. Orlando, F.A. Caprioli, F. Castiglione, C. Viganò, D.G. Ribaldone, F. Zingone, R. Monterubbianesi, N. Imperatore, S. Festa, M. Daperno, L. Scucchi, A. Ferronato, L. Pastorelli, P. Balestrieri, C. Ricci, M. Cappello, C. Felice, G. Fiorino, S. Saibeni
Circulating fibroblast activation protein as potential biomarker in patients with inflammatory bowel disease
2021 F. Corsi, L. Sorrentino, S. Albasini, F. Colombo, M. Cigognini, A. Massari, C. Morasso, S. Mazzucchelli, F. Piccotti, S. Ardizzone, G.M. Sampietro, M. Truffi
Budesonide MMX in the treatment of ulcerative colitis: Current perspectives on efficacy and safety
2021 G. Maconi, D. Camatta, R. Cannatelli, F. Ferretti, A. Carvalhas Gabrielli, S. Ardizzone